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Abstract: The etiology of inﬂ  ammatory bowel disease (IBD) has not yet been clariﬁ  ed and 
immunosuppressive agents which nonspeciﬁ  cally reduce inﬂ  ammation and immunity have 
been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of 
mucosal immunity in the gut of IBD causes an overproduction of inﬂ  ammatory cytokines and 
trafﬁ  cking of effector leukocytes into the bowel, thus leading to an uncontrolled intestinal 
inﬂ  ammation. Under normal situations, the intestinal mucosa is in a state of “controlled” inﬂ  am-
mation regulated by a delicate balance of proinﬂ  ammatory (tumor necrosis factor [TNF-α], 
interferon-gamma [IFN-γ], interleukin-1 [IL-1], IL-6, IL-12 and anti-inﬂ  ammatory cytokines 
IL-4, IL-10, IL-11). The mucosal immune system is the central effector of intestinal inﬂ  amma-
tion and injury, with cytokines playing a central role in modulating inﬂ  ammation. Cytokines 
may therefore be a logical target for inﬂ  ammatory bowel disease therapy using speciﬁ  c cytokine 
inhibitors. Biotechnology agents targeted against TNF, leukocyte adhesion, Th1 polarization, 
T cell activation, nuclear factor-kappaB (NF-κB), and other miscellaneous therapies are being 
evaluated as potential therapies for the treatment of inﬂ  ammatory bowel disease. In this context, 
inﬂ  iximab and adalimumab are currently the only biologic agents approved in Europe for the 
treatment of inﬂ  ammatory Crohn’s disease. Other anti-TNF biologic agents have emerged, 
including CDP571, certolizumab pegol, etanercept, onercept. However, ongoing research con-
tinues to generate new biologic agents targeted at speciﬁ  c pathogenic mechanism involved in 
the inﬂ  ammatory process. Lymphocyte-endothelial interactions mediated by adhesion molecules 
are important in leukocyte migration and recruitment to sites of inﬂ  ammation, and selective 
blockade of these adhesion molecules is a novel and promising strategy to treat Crohn’s disease. 
Therapeutics agents to inhibit leukocyte trafﬁ  cking include natalizumab (approved for use in 
Crohn’s disease in USA), MLN-02, and ISIS 2302. Other agents being investigated for the 
treatment of Crohn’s disease include inhibitors of T cell activation, proinﬂ  ammatory cytokine 
receptors, Th1 polarization, growth hormone, and growth factors. Agents being investigated 
for treatment of ulcerative colitis include many of those mentioned above. Controlled clinical 
trials are currently being conducted, exploring the safety and efﬁ  cacy of old and new biologic 
agents, and the search certainly will open new and exciting perspective on the development 
of therapies for inﬂ  ammatory bowel disease. A review is made of the main areas of research 
exploring the mechanisms associated with the pathogenesis of IBD, providing advances in the 
agents currently in use, and identifying a host of new therapeutic biologic targets.
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Introduction
Inﬂ  ammatory bowel diseases (IBD) are chronically relapsing intestinal inﬂ  ammatory 
conditions with a typical onset in young adulthood and with an unpredictable 
disease course that may lead to debilitating complications. Crohn’s disease (CD) 
and ulcerative colitis (UC) are two main phenotypes of IBD.1 Their etiopathogenesis 
has not been clearly elucidated but is thought to involve a complex interplay among 
genetic, environmental, microbial and immune factors. Thus, a more integrated Biologics: Targets & Therapy 2009:3 78
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approach (including different disciplines such as molecular 
microbiology, immunophysiology, and psychoneuroimmu-
nology) may provide a more complete understanding of the 
IBD’s pathogenesis.
Lifelong pharmacotherapy has remained the cornerstone 
of IBD management, whereas surgery has been relegated to 
treatment of refractory disease or speciﬁ  c complications.
Current guidelines about conventional IBD therapy 
recommend use of. aminosalicylates (sulphasalazine, 
5-aminosalicylic acid), corticosteroids, immunosuppressive 
drugs (azathioprine [AZA], 6-mercaptopurine [6-MP], 
methotrexate [MTX], cyclosporin A [CyA]), the selection of 
which depends on the clinical goal (induction or remission-
maintenance), extent and severity of disease, response to 
current or prior treatment, and the presence of complications.2 
Aminosalicylates are considered ﬁ  rst-line therapy for mild 
to moderate UC and CD; although effective in UC, induc-
ing remission in 40% to 80% of patients, with 54% to 88% 
remaining in long-term remission,3 their efﬁ  cacy is more con-
troversial in CD.4–6 The therapeutic efﬁ  cacy of 5-ASA may 
depend on the mucosal concentration. Combining topical and 
oral therapy can increase mucosal concentration 100-fold, 
which is more effective in refractory UC. A new delivery 
system also controls the colonic release of 5-ASA through a 
multi-matrix (MMX) of hydrophilic polymer and lipophilic 
excipients enclosed in a coated tablet (SPD-476). This may 
enhance mucosal delivery to the sigmoid colon.
Corticosteroids are indicated for moderate to severe UC 
or CD or for patients who do not respond to ﬁ  rst-line therapy 
and provide response rates of 45% to 90% in UC and 60% to 
78% in CD.7 Corticosteroids suppress active inﬂ  ammation in 
the acute setting, but they are ineffective maintenance agents 
with a side-effect proﬁ  le that does not allow long-term treat-
ment and they can have a high relapse rate. Moreover, most 
patients lose response to steroids over time. In addition, one 
year after starting corticosteroids, only 48% of UC and 32% 
of CD patients are corticosteroid-free without surgery,8 which 
underscores the importance of maintenance therapy after a 
steroid-induced remission.
Thiopurines (AZA, 6-MP) are effective maintenance 
immunosuppressant agents indicated for steroid-dependent 
patients9–12 or after a cyclosporine-induced remission,13 but 
are limited by their slow onset of action and potential serious 
adverse events and toxicity14 (mostly toxic hepatitis, pancre-
atitis and lymphopenia, opportunistic infections).
CyA is a more rapidly acting therapeutic option for severe 
UC and CD15 refractory to conventional therapy; however, its 
use is restricted to experienced centers equipped to monitor 
blood levels because it is associated with signiﬁ  cant and 
potential risks of hypertension, nephrotoxicity, electrolyte 
imbalance, encephalopathy, tremors, myelosuppression, oppor-
tunistic infections, and seizures.2 The current guidelines advice 
continuing AZA/6MP therapy during pregnancy because some 
studies showed no incidence difference in miscarriage, preterm 
delivery, low birth weight, or fetal malformation.
MTX has been established as an inductive agent for 
steroid-dependent CD (remission rate 39.4%) and for 
mainteinance of remission after successful induction (65% 
relapse-free after 40 weeks).16–17
However, MTX can produce potential myelosuppression, 
hepatotoxicity, and teratogenic and abortigenic effects.
In the last decade the management of refractory IBD has 
been changed dramatically by the advent of biologic therapies. 
The novel biologic agents, created with genetic technology 
and directed against a speciﬁ  c inﬂ  ammatory mediator, have 
found some of their ﬁ  rst real clinical applications in the treat-
ment of IBD. A better understanding of mucosal immune 
pathology in Crohn’s disease and the insights in the effect of 
gut mucosal cytokines and their importance in the inﬂ  amma-
tory process have led to the development of new therapies 
with selective targets in the immune pathway.18–20
We review the main areas of research and explore the 
mechanisms more intimately associated with the develop-
ment of IBD, identifying a host of new therapeutic agents 
potentially interacting with or interrupting speciﬁ  c targets in 
the pathogenesis of IBD (Tables 1 and 2).
Moreover, some guidelines summarizing the recommen-
dations for use of biologics agents in the clinical practice 
will be provided.
Pathogenetic background
Genetic factors
IBD is now thought to represent a chronic disease characterized 
by a diffuse inﬂ  ammation of the intestinal mucosa associated 
with a dysregulation of the mucosal immune system, and an 
inappropriate response of the intestinal mucosal immune 
system to otherwise innocuous luminal antigens in a geneti-
cally susceptible host.21
Although CD and UC are considered to be an adaptive dis-
ease driven by the immune system, the quest for IBD-related 
genes has indicated that in some patients, deﬁ  ciencies in the 
innate immune response can be linked to the development 
of IBD.
Genetic variations in the genes that play a role in the innate 
and adaptative immune systems are the result of an everlasting 
arms race between the human species and its environment.Biologics: Targets & Therapy 2009:3 79
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There is ample evidence that IBD are, in part, the result of 
a genetic predisposition, with multiple susceptibility genes, 
some common to both diseases and some linked separately 
to one disease or the other. Recently, a gene conferring 
susceptibility to CD was identiﬁ  ed by genome-wide screen-
ing, on chromosome 16 in families with several affected 
members.22,23
The gene, known as NOD2/CARD15, is similar to the 
R factor genes of plants conferring resistance to infec-
tion, and was designed as IBD1 locus. Mutations of the 
NOD2/CARD15 gene in this region have been conclusively 
associated with CD. NOD proteins are thought to be cyto-
solic receptors for pathogenic bacterial signals; NOD2 is 
expressed in monocytes and activates nuclear factor kappaB 
(NF-κB), which is a key transcriptional factor involved in 
the onset of immunoinﬂ  ammatory responses.24,25 However, 
there are controversial results in experimental studies about 
the relationship between mutated NOD2 and activation of 
NF-κB (decrease or increase), depending on the experimental 
settings. Mutations are no more frequent in patients with 
UC than in controls, supporting the theory that CD and UC 
are related, but different, disorders. As far as the modes 
by which the NOD2/CARD15 confers susceptibility to CD 
are concerned, two hypotheses have been advanced based 
on the molecular domains of the molecule. One is that the 
presence of the caspase activation and recognition domains 
indicates that NOD2/CARD15 plays a role in apoptosis.26
The other is that the presence of the leucine-rich repeat 
domain indicates that the NOD2/CARD15 protein has a role 
in the recognition of microbes and innate immunity, because 
regions of leucine-rich repeat are a feature of the proteins that 
identify molecular patterns of microbial products, the so-called 
pattern-recognition receptors. Thus the NOD proteins may 
represent another family of pattern-recognition receptors, 
in that NOD1 and NOD2 bind endotoxins intracellularly, 
resulting in activation of the transcription factor NF-κB, 
Table 1 Therapeutic targets and biologic agents
Target Biologic agents Phase of investigation
Inhibitors of T cell activation Anti-CD40 ligand Phase II
Anti-CD4 therapy cM-T412, MAX.16H5, B-F5 Discontinued
Anti-CD3 Visulizumab Phase III suspended
Anti-inﬂ  ammatory cytokines IL-10 Failed phase II/III
IL-11 Phase II
Inhibitors of proinﬂ  ammatory cytokines
TNF-α blockers Anti-TNF therapies: Inﬂ  iximab CDP571 Phase IV
Certolizumab pegol Failed phase III/IIa
RDP58 Phase III/IIIb
Etanercept Phase II
Onercept Failed phase II
Adalimumab Failed phase II
Phase IV
Inhibitors of proinﬂ  amatory cytokine receptor Anti-IL-6R Phase II
Inhibitors of Th1 polarization Anti-IL-2 receptor antibodies Phase II
(daclizumab, basiliximab),
Anti-IL-12 Phase II
Anti-IFN-γ (fontolizumab) Phase II
Adhesion molecule inhibitors Natalizumab Phase IV ( only in USA)
MLN-02 Phase III
ISIS 2302 Failed phase III/Phase II
Growth hormone an growth factors Human growth hormone, Epidermal Phase II
growth factor Sargramostin Phase II
Filgrastim Phase III
Phase IIa
Abbreviations: TNF, tumor necrosis factor; IL, interleukin; MLN-02, α4β7 integrin antibody; ISIS 2302, antisense oligonucleotide to intercellular adhesion molecule 1; Th, 
T helper cell; IFN, interferon.Biologics: Targets & Therapy 2009:3 80
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which, in turn, activates the production on inﬂ  ammatory 
cytokines. NF-κB is increased in the lesions of CD, as are 
numerous inﬂ  ammatory cytokines whose transcription is 
mediated by NF-κB, including tumor necrosis factor alpha 
(TNF-α), interleukin-1 (IL-1), IL-6, and IL-12. Multiple 
receptors are linked to the NF-κB signal–transduction 
pathway, such as those for the inﬂ  ammatory cytokines IL-1 
and TNF-α, which have a major role in CD, the toll-like 
receptors (TLRs), and NOD2. Thus, NF-κB is a ﬁ  nal common 
pathway for a number of inﬂ  ammatory signals, and its inhi-
bition is a rationale target for drug therapy. Moreover, any 
understanding of the contributions of NOD2/CARD15 muta-
tions to the development of CD would be not useful without a 
determination of which speciﬁ  c features or clusters of features 
of the disease are referred to as phenotypes.
Recently several more IBD susceptibility gene have been 
identiﬁ  ed. A widely replicated associated locus is the IBD5 
locus on chromosome 5q31–q33 encoding for the organic 
cation transporters 1 and 2: unfortunately, the causative IBD 
susceptibility gene from this region has not yet been unequiv-
ocally identiﬁ  ed. A recent genome-wide association scan 
identiﬁ  ed a coding single nucleotide polymorphism (SNP), 
within the autophagy-related 16-like 1 gene (ATG16L1) 
on chromosome 2q37.1, to be strongly associated with CD. 
Finally, a genome-wide association study found that genetic 
variation in the interleukin 23 receptor gene (IL23R) has a 
protective effect for developing CD.27
Environmental factors
The importance of environmental factors is supported by 
the striking increase in the frequency of CD in the more-
developed world over the past 50 years, and the increased 
recognition of the disease, with progressive industrialization 
in less developed countries. Elements within a changing 
environment that might affect development of the mucosal 
immune system, the enteric microﬂ  ora, or both, include 
improved hygiene, consumption of sterile and nonfermented 
foods, vaccination, and age at ﬁ  rst exposure to intestinal 
pathogens.28 During the last few years, with improvements 
in the socioeconomic conditions of the developing world, 
the IBD incidence is increasing. In the attempt to offer an 
explanation for temporal changes in disease frequency and 
the high prevalence of genes that predispose individuals 
to CD, it is suggested that the same genes confer selective 
advantage, such as mucosal immunoprotection in an unsani-
tary world. The effects of poor hygiene at early childhood 
are diverse. In some situations, poor hygiene can lead to 
increased pathogenic infections, but in others, it results in 
a higher exposure to harmless microorganisms and priming 
of the regulatory immune system, thus lowering the risk for 
development of IBD. With a changing environment and life-
style in an industrialized society, this advantage ceases and 
becomes a liability since it is associated with a greater muco-
sal immune responsiveness as well as the risk of progression 
from physiological to pathological mucosal inﬂ  ammation. 
The decrease in infections from helminthic parasites in the 
developed world is one aspect of this environmental hypoth-
esis, and has been mechanistically associated with the rise in 
prevalence of CD.29 Helminths are associated with a type-2 
helper T cell response (Th2), which would counterbalance 
the type-1 helper T cell response (Th1) of CD. The effects 
of poor hygiene are diverse. In some situations, poor hygiene 
can lead to increased pathogenic infections, but in others, it 
results in a higher exposure to harmless microorganisms and 
priming of the regulatory immune system, thus lowering the 
risk for development of IBD.
Other environmental factors could affect the disease 
phenotype. The effect of cigarette smoking or the opposite 
effect of this condition on the outcome of each form of IBD 
represents the most intriguing connection between environ-
mental factors and IBD. Most reports have shown that no 
smoking is a feature of patients with UC, whereas smoking 
is a feature of patients with CD.30,31 Cigarette smoking has 
been shown to affect cellular and humoral immunity,32,33 
and to increase colonic mucus production;34 whilst both 
smoking and nicotine35 have been shown to reduce colonic 
motility. Finally, results from in vivo studies have shown 
that nicotine also has an inhibitory effect on Th2 function, 
which predominates in UC, but has no effect on Th-1 cells, 
that are predominant in CD.36
Increased intestinal permeability may play a role in the 
pathogenesis of CD. A leaky intestinal barrier intensiﬁ  es 
antigen absorption, which, in turn, leads to an exaggerated 
immune stimulation, perpetuating the inﬂ  ammatory process,37 
reﬂ  ected at the systemic level by an excessive number of 
mature B cells.19 During inﬂ  ammation cytoprotective factors, 
including transforming growth factor-alpha (TGF-α), TGF-β, 
epidermal growth factor (EGF), keratinocyte growth factor 
(KGF), IL-11, and growth hormone, are released into intesti-
nal mucosa to restore the integrity of the epithelial cell barrier 
and promote epithelial restitution and repair.38
Microbial factors
Microbial agents appear to be intimately involved in the 
pathogenesis of IBD. Although available data do not convinc-
ingly incriminate a single, persistent pathogen as a universal Biologics: Targets & Therapy 2009:3 81
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cause of IBD, this hypothesis should still be considered in 
view of the possibility that these disorders may represent 
a heterogeneous group of diseases with multiple etiologies.
During the last few years Mycobacteria paratuberculosis, 
and measles virus, as well as Listeria monocytogenes have 
been implicated.18,19,28 However, despite extensive investiga-
tions on these and other organisms over the past four decades, 
no single speciﬁ  c infection has convincingly been shown to 
be critical to the pathogenesis of IBD.
The possibility that components of the normal intestinal 
ﬂ  ora could trigger, initiate, or somehow contribute to IBD is 
another unknown factor. Bacteria within the enteric lumen 
have a complex open ecosystem that is continuous with the 
external environment, and there are up to ten times more 
bacteria than there are cells in the human body. Differences 
in microbial ecology in individuals with UC and CD and 
normal individuals were not strongly supported by early 
investigations, but more recently, a signiﬁ  cant decrease in the 
number of anaerobic bacteria and Lactobacillus in patients 
with active, but not inactive, IBD has been found.39 Moreover, 
evidence of a relationship between colonic microﬂ  ora and 
the pathogenesis of UC comes from studies on genetically 
engineered animals that develop colitis when exposed to 
nonpathogenic colonic bacterial microﬂ  ora in an environ-
ment free from speciﬁ  c pathogens, but not when they are in 
a sterile germ-free environment.
It is reasonable to consider therapeutic approaches that elim-
inate the bacterial antigens and adjuvants that constantly drive 
the pathogenic immune response as a potentially important 
component in treating IBD, in concert with anti-inﬂ  ammatory 
and immunosuppressants agents. Use of narrow- and broad-
spectrum antibiotics, probiotics (beneﬁ  cial bacteria), prebiot-
ics (dietary components that foster the growth of beneﬁ  cial 
bacteria), or the combination of each of these approaches has 
considerable logic, but at the moment are supported by few 
controlled studies.
This complex interplay of genetic, microbial, and envi-
ronmental factors culminates in a sustained activation of the 
mucosal immune and nonimmune response, likely facilitated 
by defects in the intestinal epithelial barrier and mucosal 
immune system, resulting in active chronic inﬂ  ammation 
and tissue damage.
Immuno-inﬂ  ammatory factors
CD4+ cells and T-helper subsets
Under normal conditions, the intestinal mucosa is in a state 
of “controlled” inﬂ  ammation regulated by a delicate balance 
of proinﬂ  ammatory and anti-inﬂ  ammatory cytokines.
The uncontrolled inﬂ  ammatory reaction in IBD probably 
results from interplay between genetic deﬁ  ciencies in the 
innate immune system and an exaggerated T cell-driven 
adaptive immune response. The crucial role of CD4+ T cells 
in the inﬂ  ammatory cascade underlying IBD has been well 
established. Activation of these T cells is a multi-step process 
involving strict control by cytokines and membrane-bound 
cellular interaction.
Upon encountering an initiating antigen from an antigen-
presenting cell (APC), mucosal lymphocytes are activated 
to secrete IFN-γ and IL-2.
CD4+ T cells regulate critical aspects of the speciﬁ  c immune 
response. CD4+ T cells have been classiﬁ  ed as either Th1 or 
Th2 and the new Th17 (T helper 17), on the basis of function 
and according to their ability to elaborate speciﬁ  c cytokines. 
Th1 cells orchestrate cell mediated immune responses and are 
characterized by their ability to secrete IL-2, INF-γ, and TNF-β. 
IL-2 promotes the clonal expansion of T cells and enhances the 
function of T and B cells. INF-γ activates APCs and macro-
phages to produce IL-12, thereby driving Th1 cells producing 
even larger amounts of INF-γ, IL-2, and TNF-β.
Th2 cells, in contrast, mediate humoral responses and 
secrete IL-4, IL-5, IL-6, IL-10, and IL-13. These subsets 
regulate each other reciprocally through key cytokines. IFN-γ, 
produced by Th1 cells, suppresses the development of Th2, 
whereas IL-4, IL-10, and IL-13 secreted by Th2 cells inhibit 
Th1 responses.19–40 The Th17 lineage has emerged from discov-
ery of a new family of cytokines (IL-17 family) and identiﬁ  ca-
tion of new activities for the pleiotropic cytokines, TGF, and 
IL-6. Th17 cells appear to have evolved as an arm of the adapta-
tive immune system specialized for enhanced host protection 
against extracellular bacteria and some fungi or microbes 
probably not well covered by Th1 or Th2 immunity.
CD is associated with type 1 helper T cell (Th1) cyto-
kines,19,41 while UC cytokine patterns are less clear; UC does 
not ﬁ  t clearly into the Th1/Th2 dichotomy but more closely 
resembles, at least in established disease, a modiﬁ  ed Th2 
response.40,41
Thus CD4+ T cells clearly play an important role in shaping 
the immune response, and the inhibition of Th1 responses could 
represent a signiﬁ  cant goal in the treatment of IBD, especially 
of CD where the evidence of the Th1 effects is strongest.
Moreover, the main abnormality responsible for leading 
to inﬂ  ammation is now known to be an exaggerated T cell 
response causing mucosal hyper-responsiveness to commensal 
bacteria.42
Cross-reactivity of peripheral-blood and colonic-
lamina-propria CD4+ T cells with indigenous ﬂ  ora (bacteroides, Biologics: Targets & Therapy 2009:3 82
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biﬁ  dobacteria, and various enterobacteria) in patients with 
CD and UC suggests that abnormal T cell-speciﬁ  c immune 
responses to host ﬂ  ora are important in their pathogenesis.43
Intestinal Th1 activation and cytokine release is 
associated with the generation of activated matrix metal-
loproteinases which are essential mediators of tissue 
destruction.44,45
At least two mechanisms regulate activated mucosal 
T cells. The ﬁ  rst is based on the function of both the effector 
and regulator T cell subpopulations within the healthy mucosa; 
effector T cells are capable of causing intestinal inﬂ  amma-
tion, and regulatory T cells are able to control or prevent 
inﬂ  ammation.46
The second mechanism consists of end of immune 
responses by apoptosis induction in activated T cells 
once pathogens have been dealt with. In CD patients, 
mucosal T cells are resistant to apoptosis, which leads 
to accumulation of T cells and persistence of the inﬂ  am-
matory response.47,48 In UC patients, T cells in the lamina 
propria are more susceptible to Fas-mediated apoptosis.49 
Furthermore, the Fas ligand (FasL) is strongly expressed 
by T cells in active UC but not in CD lesions, suggesting 
that Fas-FasL induced apoptosis plays a part in the mucosal 
damage of UC.50
Anti-inﬂ  ammatory cytokines
IL-10
IL-10 is an antiinﬂ  ammatory cytokine produced by T cells, 
B cells and monocyte-activated lipopolysaccharides. When 
the body is presented with an antigen, IL-10 inhibits the 
production of IL-1α, IL-6, and TNF-α. Thus, it contributes to 
downregulation of acute inﬂ  ammatory responses. In animal 
models, IL-10 maintains immune homeostasis in the gut and 
may play a role in the treatment of CD.51
IL-11
IL-11 is a novel cytokine derived from mesenchymal cells. 
It has potent thrombocytopoietic properties and is used as a 
treatment for thrombocytopenia in cancer chemotherapy.52 
The evaluation of IL-11 for use in CD stems from data 
showing the positive effects of this cytokine on the mucosal 
barrier function. IL-11 attenuates the inﬂ  ammatory response 
by inhibiting expression of NF-κB and in turn IL-1, TNF-α, 
and other proinﬂ  ammatory peptides.53
Incidental findings of improved intestinal mucosal 
integrity in models of colitis injury54 led to studies of 
IL-11 on animal models of colitis, in which a beneﬁ  t was 
observed.55,56
Th1 polarization
IL-2
IL-2 is a critical cofactor for the initiation and continuation 
of a speciﬁ  c immune response. IL-2 is produced by native 
T cells after activation. At the same time, activated T cells 
elaborate IL-2 receptor, completing an autocrine and para-
crine loop-promoting clonal expansion. IL-2 has important 
effects on other immune cells, including B cells, monocytes, 
and natural killer (NK) cells.18,19,57
IFN-γ
IFN-γ is elevated in all genetic animal models of IBD and 
seems to be critical in the development of Th1 responses. If 
the target of IBD therapy is to reduce Th1 responses, then 
direct neutralization of IFN-γ is a rational approach. Sur-
prisingly, anti-IFN-γ administered to IL-10 knock-out mice 
showed no beneﬁ  t. It is also demonstrated in experimental 
induced colitis that ablation of IFN-γ gene in T cells does 
not prevent the disease.18,19,57
IL-12/IL-17/IL-23
IL-23 is a heterodimeric cytokine composed of a p19 subunit 
and the p40 subunit of IL-12. It is produced by macrophages 
and dendritic cells, and activates memory T cells. IL-12 is 
composed of p35 and p40 subunits and acts as an important 
factor for the differentiation of naive T cells into T-helper 
type 1 CD4+ lymphocytes secreting IFN-γ. Therefore it has 
been reported that IL-12 is crucial for T cell-dependent 
immune and inﬂ  ammatory responses through the use of 
IL-12 p40 gene-targeted mice and neutralizing antibodies 
against p40. Apparently IL-12 is a key factor driving Th1 
responses and IFN production in the initial phases of an 
immune response, but conversely IL-12 may play a sub-
sequent immunoregulatory role in late-stage inﬂ  ammation 
at a point when IL-23 strongly supports the inﬂ  ammatory 
process. IL-23 induces the production of IL-17 by a unique 
subset of memory T cells. IL-17 is known to stimulate 
ﬁ  broblasts, endothelial cells, macrophages, and epithelial 
cells to secrete multiple proinﬂ  ammatory mediators and 
the local production of IL-17 causes site-speciﬁ  c activation 
of inﬂ  ammatory cells. Dendritic cells found in the lamina 
propria of the small intestine were described as constitu-
tively expressing IL-23, whereas IL-23 regulates a highly 
potent T cell-derived cytokine that has major actions on 
the immune system. IL-23 speciﬁ  cally stimulates memory 
CD4+ T cells contrasting the IL-12 which is a stimulant for 
naive CD4+ T cells. Studies with IL-23 deﬁ  cient mice show 
that IL-23 is essential for the manifestation of intestinal Biologics: Targets & Therapy 2009:3 83
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inﬂ  ammation and a dominant role for IL-23 over IL-12 in 
central nervous system and joint autoimmune inﬂ  ammation 
has been described. These ﬁ  ndings point to IL-23, but not 
IL-12, as the necessary mediator for organ speciﬁ  c autoim-
mune diseases development.18,19,57–59
IL-18
IL-18 is a recently described cytokine that mainly exists in 
activated macrophages and epithelial cells and shares bio-
logical activities with IL-12 in driving the development of 
Th1 by inducing IFN-γ. IL-18 is upregulated in the intestinal 
mucosal cells of patients with IBD60 and animal models 
have shown beneﬁ  t of anti-IL-18 antibodies in reducing the 
severity of colitis.61
Proinﬂ  ammatory cytokines
IL-1 and TNF-α
IL-1 and TNF-α share a multitude of proinflammatory 
properties and appear to be critical to the ampliﬁ  cation of 
mucosal inﬂ  ammation in IBD. Both cytokines are primarily 
secreted by monocytes and macrophages upon activation, and 
induce intestinal macrophages, neutrophils, ﬁ  broblasts, and 
smooth-muscle cells to elaborate prostaglandins, proteases, 
and other soluble mediators of inﬂ  ammation and injury, as 
well as other inﬂ  ammatory and chemotactic cytokines. An 
enhanced expression of IL-1 and TNF was found in IBD, 
and the important role of TNF was also conﬁ  rmed in the 
genesis of these diseases. The effects of TNF in the intestine 
which may play a role in mucosal inﬂ  ammation are disrup-
tion of the epithelial barrier, induction of apoptosis of the 
villous epithelial cells and secretion of chemokines from 
the intestinal epithelial cells. TNF activates endothelium by 
upregulating E-selectin and other adhesion molecules such 
as intercellular adhesion molecule-1 (ICAM-1) as well as by 
inducing the expression of cytokines and chemokines. TNF 
also activates neutrophils and macrophages and stimulates 
B cells. It increases the production of IFN-γ by mucosal 
T cells independently of IL-12 and IL-18.
It activates CD44 in T cells and enhances intraepithelial 
lymphocyte proliferation and migration. TNF also stimulates 
stromal cells from the fetal gut to produce matrix metal-
loproteinases (MMPs), which could lead to tissue injury, 
mobilizes dendritic cells from the intestine and appears to be a 
determinant in granuloma formation,66 and in association with 
IL-6, IL-1 may contribute to the constitutional symptoms 
of IBD and lead to the generation of acute phase proteins.62
TNF-α is translated as a precursor protein which contains 
an unusually long signal peptide that anchors the protein to 
the outer membrane. During local and systemic inﬂ  ammatory 
reactions, membrane bound TNF-α is cleaved extracellularly 
by a speciﬁ  c zinc-dependent metalloprotease that has been 
designated TNF-α converting enzyme (TACE), yielding the 
soluble homotrimeric form of TNF-α that can act either as a 
compartmentalized or circulating cytokine.
It was initially thought that cleavage of TNF-α constituted 
a major ﬁ  nal road block for TNF-α production but subse-
quently it was recognized that membrane expressed TNF-α is 
biologically active as a homotrimer during cell-cell contact by 
interacting with both p55 and p75 TNF receptors.67,68 TACE is 
member of the ADAM (a disintegrin and metalloproteinase) 
family of cell surface proteases, which are induced during 
inﬂ  ammation.69,70
Potential sites for therapeutic manipulation along TNF 
production, processing, and secretion pathway are shown 
in Figure 1.
IL-6
IL-6 is a pleiotropic cytokine with a central role in immune 
regulation, inﬂ  ammation, and hematopoiesis.71 Increased 
serum concentrations of IL-6 and soluble IL-6 receptor 
(IL-6R) have been correlated to clinical activity of CD, 
and animal models have strongly suggested the therapeutic 
potential of anti-IL-6R monoclonal antibody in CD.72,73
Peroxisome proliferator-activated receptors
Peroxisome proliferator-activated receptors (PPARs) are 
members of the nuclear hormone receptor superfamily of 
transcription factors whose activities are regulated by high 
afﬁ  nity binding of small lipophilic ligands such as steroid 
hormones.74
A new class of antidiabetic drugs, thiazolidinediones, 
has been developed that bind to the γ subtype of the PPARs. 
Colonic epithelial cells express high levels of PPARs 
proteins, and have the ability to produce inﬂ  ammatory 
cytokines that may contribute to the inﬂ  ammatory process 
in UC.75
Adhesion molecules and leukocyte 
recruitment
Lymphocyte inﬁ  ltration into the intestinal tract in IBD 
is mostly mediated by intectation between α4β7 integrin 
expressed on lymphocyte and one of its speciﬁ  c ligand 
mucosal vascular addressin CAM-1 (MAdCAM-1), 
expressed on the endothelial cells of the microvascu-
lature in the inﬂ  amed intestinal tract. Integrins form a 
large family of transmembrane proteins required for cell Biologics: Targets & Therapy 2009:3 84
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adhesion, attachment of the cell to the extracellular matrix, 
or to other cells and anchorage of the cytoskeleton to 
the plasma membrane. Alfa4 integrins are necessary not 
just for lymphocyte homing, but also for activation and 
signaling as well as interaction with extracellular matrix 
protein. In the pathogenesis of IBD, both T-lymphocyte 
migration into inﬂ  amed mucosa and local activation and 
proliferation contribute to the perpetuation of inﬂ  ammation. 
Lymphocyte trafﬁ  cking into the intestinal mucosa is a 
multi-step process mediated by three essential steps: 
rolling, adherence and transendothelial migration.76,77
Development of monoclonal antibodies against α4 integ-
rin could permit the targeting of lymphocyte trafﬁ  cking into 
the intestine as a novel therapeutic intervention.
Each of the pathogenic mechanisms elucidated above 
offers a potential target for novel therapeutic intervention.
Figure 2 illustrates the targets of biologic therapy.
Deﬁ  nition of biologic therapy
Biologic therapies encompass agents with diverse modes of 
action. They include: (1) native biologic preparations such 
as blood products and vaccines containing live, attenuated, 
or killed micro organisms; (2) recombinant peptides 
or proteins such as growth hormone, erythropoietin, 
and soon; (3) antibody-based therapy; (4) nucleic acid-
based therapies; and (5) cell and gene therapy.78 At this 
time, the biotechnology therapies that are being used 
in clinical practice or investigated for the treatment of 
IBD are predominantly proteins, usually delivered intra-
venously or subcutaneously. The types of therapeutic 
proteins in use include recombinant human proteins 
with immunoregulatory effects, monoclonal antibodies 
(chimeric, humanized, and fully human), and fusions 
proteins.79 These small molecules can be screened for 
a speciﬁ  c activity against a speciﬁ  c targeted step in the 
pathogenesis of IBD (initiation, stimulation or perpetuation 
of mucosal inﬂ  ammation).
Compared to the development of most compound-
based drugs, development of biologic agents has been 
relatively rapid. Biologic agents are often developed by 
selection of candidate peptides of identiﬁ  ed physiologic 
function.
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Figure 1 Activation pattern leading to TNF production and sites of potential TNF antagonism. Each activation pathway may vary depending on the cell type. The circled numbers 
show each step in TNF production and secretion pathway, which may be a potential target for therapeutic manipulation using speciﬁ  c inhibitors. Oxypentifylline and other 
type IV phosphodiesterase inhibitors interfere with gene expression at step I. Mesalazine inhibits TNF-mediated effects on intestinal epithelial cell proliferation at steps 1 and 2. 
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Therefore, the time for preclinical development may be 
relatively short and potentially expensive.
Manipulation of 
immunoinﬂ  ammatory factors
Inhibitors of T cell activation
CD40 ligand
CD40 ligand (CD40L), expressed on T-lymphocytes after 
their interaction with an APC, is an important costimula-
tory molecule involved in T cell activation. CD40L binds 
CD40 (expressed on the APC) to stimulate the expression 
of yet another costimulatory molecule, B7 (on the APC 
membrane), which in turns binds to CD28 on the cell 
surface.80 Inhibition of the cell activation by targeting these 
molecules is an attractive concept and a potential therapeutic 
intervention. A humanized monoclonal antibody to CD40L, 
IDEC-131, has been developed and a phase II trial initiated 
for CD. However, owing to concerns of thromboembolism, 
this trial has been halted.81 Recently a Italian study group 
demonstrated that engagement of CD40 in human intestinal 
ﬁ  broblast promoted the release of vascular EGF, IL-8, and 
hepatocyte growth factor.82 Thus, the CD40–CD40 ligand 
pathway appears to be crucially involved in regulating 
inflammation-driven angiogenesis, target of a potential 
therapeutic approach.
Anti-CD4 antibodies
Anti-CD4 antibodies have been used in a variety of autoim-
mune diseases, and have also been tested in CD and UC.
A CD4 depleting antibody (cM-T412) was tested in two 
open studies.83,84 Both CD and UC patients achieved clini-
cal and endoscopic improvement/remission after a period of 
treatment varying from seven to 11 days.
In another three open trials,85–87 CD4 nondepleting anti-
bodies (MAX.16H5 and B-F5) were administered to a total 
of 16 CD and nine UC patients with active disease. Of the 
nine UC patients, ﬁ  ve achieved remission versus only six 
of 16 CD patients. Thus, CD4 depleting antibodies seem 
to be more effective means of therapy than nondepleting 
antibodies. However, this mode of treatment was mostly 
associated with a signiﬁ  cant decrease in CD4 cells, and 
because of concerns of CD4 lymphopenia, no further studies 
have been performed.
Anti-CD3 antibodies
Visilizumab (UhM291) is a humanized CD3ε chain of the 
T cell receptor expressed on activated T cells. Visilizumab 
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may induce activated T cell apoptosis and production of 
IL-10, a potent anti-inﬂ  ammatory cytokine.88 In a phase I 
dose-escalation study, seven patients with severe steroid-
refractory UC received two infusions of visilizumab 15 μg/kg 
one day apart. Data were available only for ﬁ  ve patients, all 
achieving clinical and endoscopic remission that persisted 
for several months after treatment. Three of ﬁ  ve patients 
discontinued steroid treatment. Adverse events encountered 
included transient decrease in T lymphocyte counts and 
cytokine-release symptoms. There were no infective compli-
cations.89 The phase I dose ranging study in UC patients has 
been reported,90 but sadly the phase III study was suspended 
in 2007 when interim analysis showed no beneﬁ  t.
Anti-inﬂ  ammatory cytokines
IL-10
A dose-response, placebo-controlled study reported that 
therapy with recombinant IL-10 (rHuIL-10) at doses of 
0.5, 1, 5, 10, or 25 μg/Kg intravenously for seven days was 
beneﬁ  cial in 46 refractory CD patients.91 However, these 
encouraging preliminary results were not conﬁ  rmed by three 
large placebo-controlled dose-response trials in patients with 
mild to moderately active or chronically active CD.
In the ﬁ  rst,92 329 patients with CD refractory to treatment 
were given subcutaneous human recombinant (rhu) IL-10 1, 4, 
8, 20 μg/kg or placebo, for 28 days. No statistically signiﬁ  cant 
difference was found between these treatment groups. How-
ever, a tendency toward clinical improvement but not remission 
was observed in the 8 μg/kg dose group. In the second trial,93 
95 patients with mild to moderately active CD were treated 
with subcutaneous (rhu) IL-10 1, 5, 10, 20 μg/kg, or placebo 
for 28 days. At the end of the treatment, clinical remission and 
endoscopic improvement was achieved in 23.5% of patients 
receiving 5 μg/kg (rhu) IL-10 vs 0% of patients in the placebo 
group. In the last study, 373 patients with CD who required 
prednisone or prednisolone (15–25 mg/daily) to maintain 
CDAI   150 were treated with (rhu) IL-10 4, 8 μg/kg, or pla-
cebo once daily subcutaneously for two weeks, then three times 
each week for 26 weeks. At end of 28 weeks of (rhu) IL-10 treat-
ment, intention-to-treat analysis demonstrated no signiﬁ  cant 
difference in the prednisone withdrawal and clinical remission 
rates between the different (rhu) IL-10 doses and placebo.94 
Finally, a phase II placebo-controlled dose response trial of 
(rhu) IL-10 failed to show a beneﬁ  cial effect in 94 patients 
with mild to moderately active UC.95
Development of systemic administration of (rhu) IL-10 by 
intravenous or subcutaneous routes for the indications of UC 
and CD has been discontinued because of a lack of efﬁ  cacy in 
these controlled trials. Recent animal studies have suggested 
that local administration of IL-10 to the colon via genetically 
engineered lactococcus bacteria that are orally administered 
may result in high colonic mucosal concentrations of IL-10 
and potentially enhanced efﬁ  cacy.96 It is possible that this 
approach to IL-10 therapy will be an alternative IL-10 thera-
peutic approach for UC and CD patients.
IL-11
Results of two clinical trials with recombinant human IL-11 
(rhIL-11) in patients with CD have been reported thus far. In 
a placebo-controlled safety study in 76 patients with active 
CD, subcutaneously administered rhIL-11 was shown to be 
safe and well tolerated.97
In a second placebo-controlled study in 148 patients com-
paring two doses of subcutaneously administered rhIL-11, 
it was signiﬁ  cantly superior in inducing remission after six 
weeks when compared to placebo, although the placebo 
Table 2 Comparison of compound-based drugs and biologic agents78
Compound-based drugs Biologic agents
Composition “Small molecule” compound Peptide, protein, RNA, DNA
Route of administration Oral, parenteral, topical Typically parenteral
Discovery and Development Usually by large-scale screening of 
compound libraries to identify parent 
drugs; chemical manipulation to alter 
characteristics
Choice of target deﬁ  ned by mechanism 
of disease. Development often by 
recombinant techniques
Cost Expensive to develop, less expensive 
to produce
Relatively less expensive to develop, more 
expensive to produce
Time to clinical trial Relatively long Relatively brief
Examples Classic receptor blockers, enzyme 
inhibitors, corticosteroids, immune 
modulators
Recombinant cytokines, cytokine receptor 
antagonists, chimeric and humanized 
antibodies, antisense oligonucleotides, 
somatic transgene vaccinationBiologics: Targets & Therapy 2009:3 87
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rate was high (36.7% vs 16.3%).98 The safety proﬁ  le of this 
regimen appeared to be excellent, with only minor injec-
tion site reactions occurring more frequently among treated 
patients.
The efﬁ  cacy of rhIL-11 was compared to prednisolone in 
patients with mild to moderate active CD (CDAI 220–400). 
In a double-blind, placebo-controlled trial, 51 patients were 
treated with rhIL-11 (1 mg/weekly) or prednisolone (starting 
dose 60 mg/daily), for a 12-week follow-up period. At the 
end of the study, rhIL-11 and prednisolone induced long-term 
remission (12 weeks) in comparably sized subsets (22% and 
21%, respectively) of patients with mild to moderate CD.99
Inhibitors of proinﬂ  ammatory cytokines
TNF blockers
Inﬂ  iximab
Among the various biologic agents, inﬂ  iximab has received 
the most attention, and is a biologic agent approved in the 
USA and Europe for the treatment of patients with moderate 
to severe CD unresponsive to conventional therapy or a full 
and adequate course of corticosteroids and immunosuppres-
sive therapy, and to patients with actively draining ﬁ  stulas. 
Recently it was approved also for the treatment of moderate-
to-severe UC refractory to conventional therapy.
Inﬂ  iximab is a monoclonal chimeric antibody, targeting 
human TNF-α, composed of a human constant region IgG1k 
light chain, accounting for approximately 75% of antibody, 
linked to a mouse variable region (25%).57 Inﬂ  iximab is 
known to bind soluble bioactive TNF in the intestinal mucosa 
and thereby neutrolize its effect. Inﬂ  iximab also binds to 
membrane-bound TNF and leads to the in vitro destruction 
of immune cells by antibody-dependent cellular toxicity. 
Additionally, it has been shown to induce T cell apoptosis.64 
Antagonism of membrane-bound TNF may be particularly 
important for the long term clinical effects of inﬂ  iximab. 
Binding of inﬂ  iximab to membrane-bound TNF on activated 
T cells has been shown to promote apoptotic T cell death.64
Initial open label studies,100,101 in which infliximab 
was effective in rapidly inducing clinical and endoscopic 
improvement/remission, have been conﬁ  rmed in several 
controlled studies.
In the first randomized, placebo-controlled trial, 
108 patients with moderate-to-severe CD which is resis-
tant to conventional therapy, were treated with the single 
intravenous infusion of either placebo or inﬂ  iximab at the 
dose of 5, 10, or 20 mg/Kg. The rate of clinical response at 
four weeks were 81% for 5 mg/kg, 50% for 10 mg/Kg and 
64% for 20 mg/Kg, all of which were signiﬁ  cantly higher 
than that for the placebo-treated group. A good result also 
for clinical remission at four weeks (33% inﬂ  iximab vs 4% 
placebo).102
Patients who maintained their response eight weeks 
after treatment (73/108 patients initially randomized) were 
re-randomized at week 12 to placebo or 10 mg/kg inﬂ  iximab 
every eight weeks for four additional infusions. A trend 
toward signiﬁ  cance was observed in the response at week 44 
(eight weeks after the last infusion) in the inﬂ  iximab-treated 
patients, compared with those receiving placebo. Quality 
of life was consistently better and serum C-reactive protein 
(CRP) levels were consistently lower in patients receiving 
inﬂ  iximab. A signiﬁ  cant difference was seen in the rate of 
remission at week 44 between inﬂ  iximab and placebo group 
(52.9% vs 20%, p = 0.013). These data suggest that repeated 
dosing with inﬂ  iximab may provide useful maintenance 
therapy, particularly in those patients initially achieving 
remission.103 The effectiveness of inﬂ  iximab for the main-
tenance therapy for inﬂ  ammatory CD was assessed in a 
large trial called ACCENT I.104 In this study 573 patients 
responders to a single infusion of inﬂ  iximab 5 mg/kg were 
randomly assigned repeat infusions of placebo at weeks 2 
and 6 and then every eight weeks thereafter until week 46 
(group I), repeat infusions of 5 mg/kg inﬂ  iximab at the same 
time-points (group II), or 5 mg/kg inﬂ  iximab at weeks 2 
and 6 followed by 10 mg/kg (group III). Three hundred and 
thirty-ﬁ  ve patients (58%) responded to a single infusion of 
inﬂ  iximab within two weeks. At week 30, 23/110 (21%) 
group I patients were in remission, compared with 44/113 
(39%) group II and 50/112 (45%) group III.
Inﬂ  iximab safety was consistent with that seen in other 
trials in CD, and the incidence of serious infections was 
similar across treatment groups.
In addition, an analysis comparing the scheduled and 
episodic treatment strategies was conducted based on the 
ACCENT I data. The efﬁ  cacy of the scheduled therapy was 
better than episodic strategy in terms of CDAI score, clinical 
remission and response rates, anti-inﬂ  iximab antibodies 
production, improvement in IBDQ score, mucosal healing 
and CD-related hospitalization and surgery.105
For an evaluation of the inﬂ  iximab maintenance therapy 
for ﬁ  stulizing CD, ACCENT II trial was conducted. One 
hundred and ninety-six CD patients, with draining perianal 
and enterocutaneous ﬁ  stulas who responded to the induction 
inﬂ  iximab 5 mg/kg therapy (weeks 0, 2, 6), received either 
placebo or inﬂ  iximab at the same dose every eight weeks. 
The median time to the loss of response, response rate and 
complete ﬁ  stula closure rate at week 54 in the inﬂ  iximab Biologics: Targets & Therapy 2009:3 88
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maintenance group were signiﬁ  cantly greater than those in 
the placebo group.106
However, reopening of ﬁ  stulae is frequent, suggesting the 
persistence of deep ﬁ  stula tracts despite superﬁ  cial healing. 
Despite closure, most ﬁ  stula tracts are still detectable at anal 
endosonography (AE), and the persistence of the internal 
tract is a condition at higher risk of ﬁ  stula recurrence. For 
these reasons, regular AE or magnetic resonance evaluation 
may have an important role in deﬁ  ning patients with perianal 
ﬁ  stulizing CD to be treated (or re-treated) with inﬂ  iximab. 
Moreover, short-term regimen doses with inﬂ  iximab and 
long-term treatment trials are necessary.
Initially, inﬂ  iximab did not seem to have much therapeu-
tic effect on UC. Two small pilot trials showed disappointing 
results for the drug in the treatment of refractory UC.107,108
Deﬁ  nitive evidence for the role of inﬂ  iximab in the 
treatment of UC has been recently offered by the two large 
placebo-controlled clinical trials ACT 1 and ACT 2.
In the ACT 1 study,109 364 patients with active UC despite 
use of corticosteroids/AZA/6-MP, with endoscopic evidence 
of moderate or severe UC (endoscopy score   2) and a total 
Mayo score of 6–12 inclusive, were randomized to receive 
placebo, inﬂ  iximab 5 mg/kg or 10 mg/kg at weeks 0, 2, and 
6 then every eight weeks through to week 46. Signiﬁ  cantly 
higher proportion of patients receiving inﬂ  iximab 5 mg/kg 
(64%) and 10 mg/kg (61.5%) had a clinical response at 
week 8 versus placebo-treated patients (37.2%). At week 30, 
52.1% and 50.8% of inﬂ  iximab-treated patients, respectively, 
achieved clinical response versus 29.8% of placebo-treated 
patients. At week 8, 38.8% and 32.0% of inﬂ  iximab 5- and 
10 mg/kg-treated patients, respectively, achieved clinical 
remission versus 14.9% of placebo-treated patients. These 
differences in remission rates persisted at week 30 (33.9%, 
5 mg/kg; 36.9%, 10 mg/kg versus 15.7%, placebo). Mucosal 
healing was achieved at week 8 in 62% and 59% of patients 
receiving inﬂ  iximab 5 and 10 mg/kg, respectively, versus 
33.9% of placebo-treated patients. This difference in mucosal 
healing was maintained at week 30 (50.4%, 5 mg/kg, 49.2%, 
10 mg/kg versus 24.8%). The proportion of patients who were 
able to discontinue corticosteroids while in clinical remission 
at week 30 was greater in the combined inﬂ  iximab treatment 
group than in the placebo group (21.7% versus 10.1%).
In the ACT 2 study,109 364 patients suffering from UC, 
refractory to at least one standard therapy including 5-ASA, 
corticosteroids or immunosuppressants, were randomized to 
receive inﬂ  iximab 5 mg/kg, inﬂ  iximab 10 mg/kg, or placebo 
at weeks 0, 2, 6, 14, and 22. Signiﬁ  cantly more patients 
with inﬂ  iximab 5 mg/kg (64.5%) and 10 mg/kg (69.2%) 
achieved clinical response at week 8 versus 29.3% who 
received placebo. At week 30, 47.1% of patients receiving 
inﬂ  iximab 5 mg/kg and 60% receiving 10 mg/kg were in 
clinical response versus 26% of patients receiving placebo. 
Clinical remission was performed at week 8 in 33.9% and 
27.5% of inﬂ  iximab 5 and 10 mg/kg patients, respectively, 
compared to 5.7% of placebo-treated patients. Differences 
in remission rates persisted at week 30 (25.6%, 5 mg/kg; 
35.8%, 10 mg/kg; 10.6%, placebo). Mucosal healing was 
achieved at week 8 in 60.3% and 61.7% of patients receiving 
inﬂ  iximab 5 mg/kg and 10 mg/kg, respectively, compared to 
30.9% of placebo-treated patients. Mucosal healing at week 
30 was achieved in 46.3% and 56.7% of patients receiving 
inﬂ  iximab 5 mg/kg and 10 mg/kg, respectively, versus 30.1% 
of placebo-treated patients. The proportion of patients who 
were able to discontinue corticosteroids while in clinical 
remission at week 30 was signiﬁ  cantly greater in both inf-
liximab groups compared with the placebo group (18.3%, 
5 mg/kg; 27.3%, 10 mg/kg; 3.3% placebo).
In both trials, infliximab was well tolerated with a 
safety proﬁ  le similar to that previously reported. Thus, in 
patients with moderate-to-severe UC, inﬂ  iximab induces and 
maintains clinical response, clinical remission and mucosal 
healing, and permits the tapering of corticosteroids while 
maintaining remission.
Some studies and very few data are available for treatment 
of indeterminate colitis with inﬂ  iximab.110,111 They suggested 
that patients with indeterminate colitis are more refractory 
to inﬂ  iximab.
Many case reports and small series have been published 
on the use of inﬂ  iximab for treating extraintestinal manifesta-
tions of IBD. Thus, inﬂ  iximab has been reported to be effec-
tive in the treatment of pyoderma gangrenosum,112 uveitis and 
spondyloarthropathy associated with IBD.113,114
Recent data suggest that initial treatment of the disease 
with the combination of AZA and inﬂ  iximab, a so called 
“top-down” approach, may be much more effective than 
the traditional step-up approach using the inﬂ  iximab only in 
therapy-refractory CD.115
This study included 100 CD patients with a CDAI greater 
than 220 who were never treated with steroids, immunomod-
ulators, or inﬂ  iximab. Patients were randomized to receive 
treatment with either three inﬂ  iximab infusions (weeks 0, 
2, 6) and AZA, topical budesonide (9 mg/day), or systemic 
prednisone (40 mg/day), to be repeated as clinically neces-
sary. In the top-down group, relapsing patients were given 
repeated inﬂ  iximab and steroids when they failed to respond 
to inﬂ  iximab. In the step-up group, inﬂ  iximab was given Biologics: Targets & Therapy 2009:3 89
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only after failure of immunosuppression. For the top-down 
approach, a signiﬁ  cantly higher remission rate at six months 
(74.5%) was noted when compared with the step-up group 
(48.1%). Top-down patients also did signiﬁ  cantly better on 
endoscopic mucosal healing, steroid usage and development 
of ﬁ  stulas. The success of the top-down approach cannot be 
accounted for by inﬂ  iximab solely, as AZA was administered 
from the start as a maintenance treatment as well.
Although inﬂ  iximab is well tolerated in the majority of 
patients, serious side effects may rarely occur, including seri-
ous infections (see below), drug-induced lupus acute infusion 
reactions, delayed hypersensitivity reactions, demyeliniation, 
possibly an increased risk of lymphoma, cardiac failure, and 
death.116,117 In clinical trials, infections requiring treatment 
occurred in 32% of inﬂ  iximab-treated patients versus 22% 
of placebo-treated patients. There was no signiﬁ  cant increase 
in serious infections or sepsis, but pneumonia, sepsis, miliary 
tuberculosis, and disseminated coccidiomycosis were all 
observed. In post-marketing surveillance, tuberculosis, 
histoplasmosis, listeriosis, aspergillosis, and pneumocystis 
pneumonia have all been observed, leading to death in some 
instances. As far as tuberculosis is concerned, reactivation of 
latent tuberculosis is a severe complication with all anti-TNF 
strategies. By February 2003, active tuberculosis was reported 
in 350 of more than 400,000 patients treated with inﬂ  iximab 
or a cumulative incidence of 0.46 per 1000 patient-years. 
Most cases occurred within the ﬁ  rst two months after initia-
tion of therapy. The cumulative mortality amounted to 9%. 
All patients who are candidate to a treatment with an anti-TNF 
agent should be evaluated for latent tuberculosis with a tuber-
culin test and chest X-ray. Treatment of latent tuberculosis 
should be initiated before therapy with inﬂ  iximab.
The presence of murine elements in monoclonal antibod-
ies is associated with a risk of immunogenicity. In a prospec-
tive study of 125 inﬂ  iximab-treated patients, 61% of patients 
developed antibodies to inﬂ  iximab (ATI, formerly called 
HACA) after the ﬁ  fth infusion.118,119 These ATI were clearly 
associated with infusions reactions and loss of response to the 
drug. Concomitant immunosuppression with AZA, 6-MP, or 
MTX was able to prevent the formation of ATI.
It is recommended that inﬂ  iximab-treated patients be put 
on a concomitant immunosuppressive agent to reduce the 
risk of ATI formation and hence reduce the risk of infusion 
reactions and prolong the duration of response.
There have been several attempts to explain the lack of 
response observed in about 30% of patients, varying from 
studies investigating clinical characteristics,119,120 (auto) 
antibodies,121,122 and genetic polymorphisms.121,123,124
In a study on 226 CD patients, the response rate was 
signiﬁ  cantly higher in patients with elevated CRP ( 5 mg/l) 
than in patients with normal CRP values ( 5 mg/l) before 
treatment (76% versus 46%), suggesting that response was 
associated with higher systemic inﬂ  ammation.125 The only 
replicated predictor of response so far has been the concomi-
tant use of an immunosuppressive.119,120
CDP571
CDP571 is a humanized IgG4 anti-TNF-α antibody with 95% 
human and 5% murine protein, that is administered intrave-
nously. and has been studied in active CD. A phase II dose-
ﬁ  nding trial demonstrated the short term beneﬁ  t of CDP571 
10 mg/kg for inducing a clinical response at two weeks 
in patients with active CD.126 A phase III trial of CDP571 
10 mg/kg again showed short-term beneﬁ  t for inducing clini-
cal response at two weeks in patients with active CD but no 
signiﬁ  cant difference at 28 weeks with maintenance dosing 
every eight weeks.127 A post-hoc analysis of a subgroup of 
patients with CRP concentrations  10 mg/l demonstrated 
signiﬁ  cantly increased response rates for CDP571 10 mg/kg 
at both two weeks and 28 weeks. Two controlled trials failed 
to demonstrate a steroid sparing beneﬁ  t of CDP571 in patients 
with steroid-dependent CD.128 From these results, CDP571 
was considered to be safe but not as effective as inﬂ  iximab 
and further clinical development of CDP571 for the treatment 
of CD has been discontinued.
Certolizumab pegol
Certolizumab pegol (CZP) is a humanized TNF-α Fab’ 
monoclonal antibody fragment linked to polyethylene 
glycol that is administered subcutaneously. The PEGylation 
increases the plasma half life of CZP to approximately two 
weeks, but it is unlikely to induce in vivo apoptosis. A large 
double-bind, placebo-controlled phase III trial, the PRECISE 
program, is composed by four studies (PRECISE 1, 2, 3, 4). 
PRECISE 3 and 4 are ongoing as part of the WELCOME 
study, designed to examine the effects of CZP in patients 
failing or intolerant to inﬂ  iximab.
In the PRECISE 1,129 662 patients with moderate to severe 
CD were stratiﬁ  ed according to baseline levels of CRP and 
were randomly assigned to receive either 400 mg of CZP or 
placebo subcutaneously at weeks 0, 2, 4, and then every four 
weeks. Primary end points were the induction of a response 
at week 6 and a response at both weeks 6 and 26. Among 
patients with a baseline CRP level of at least 10 mg /l, 37% of 
patients in the CZP group had a response at week 6, as com-
pared with 26% in the placebo group. At both weeks 6 and 26, Biologics: Targets & Therapy 2009:3 90
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the corresponding values were 22% and 12%, respectively. 
In the overall population, response rates at week 6 were 35% 
in CZP group and 27% in the placebo group; at both week 6 
and 26 the response rates were 23% and 16%, respectively. 
At weeks 6 and 26, the rates of remission in the two groups 
did not differ signiﬁ  cantly. Serious adverse events were 10% 
in CZP group, compared to 7% in the placebo group. This 
study showed that induction and maintenance therapy with 
CZP was associated with a modest improvement in response 
rates, compared to placebo, but with no signiﬁ  cant improve-
ment in remission rates.
Design of the study was different in the PRECISE 2:130 
as induction therapy, 400 mg of CZP was administered 
subcutaneously at weeks 0, 2, and 4. Patients with a clinical 
response (CDAI reduction of at least 100 from baseline) at 
week 6 were randomly assigned to receive 400 mg of CZP 
or placebo every four weeks through week 24 with follow 
up through week 26.
At week 6, 64% of patients achieved a clinical response 
that was maintained through week 26 in 62% of patients with 
a baseline CRP level of at least 10 mg/l who were receiving 
CZP (versus 34% of those receiving placebo) and in 63% of 
patients in intention-to-treat population who were receiving 
CZP (versus 36% receiving placebo). Among patients with 
a response at week 6, remission (reduction of CDAI at least 
150) at week 26 was achieved in 48% of CZP patients and 
in 29% of placebo group. Serious adverse events (includ-
ing one case of pulmonary tuberculosis) occurred in 3% of 
patients receiving CZP and less than 1% of patients receiving 
placebo.
In conclusion, the patients with a response to induction 
therapy with CZP were more likely to have a maintained 
response and a remission at week 26 with CZP treatment 
than with placebo.
Actually, CZP is available for clinical use in CD in USA 
but not in Europe. Results from ongoing studies are eagerly 
awaited.
RDP58
RDP58 is a novel anti-inﬂ  ammatory decapeptide able to 
block TNF production at a post-transcriptional step,131 and 
also inhibits production of IFN-γ, IL-2, and IL-12. RDP58 
has been shown to be effective in murine and primate models 
of colitis.132,133 In a phase II study,134 127 patients with 
mild-to-moderate active UC were randomized to receive 
placebo or an oral solution of RDP58 at 100, 200, or 300 mg 
daily for 28 days. Clinical remission was achieved in 72% 
of patients in the 300-mg group, 70% in the 200-mg group, 
29% in the 100-mg group, and 40% in the placebo group, with 
response rates of 72%, 77%, 33%, and 44%, respectively. 
There were no differences in adverse events among any of 
the treatment groups compared with placebo.
Studies in CD have also begun and results from future 
trials are awaited.
Etanercept
Etanercept is a genetically engineered fusion protein consist-
ing of two recombinant human TNF p75 receptors linked to 
an Fc portion of human IgG1 fragment. The subcutaneous 
injection of etanercept at the dose of 25 mg twice weekly, 
which is an effective dose for rheumatoid arthritis, is a safe 
but ineffective dose for the treatment of patients with moder-
ate to severe CD.135
Onercept
Onercept is a fully human recombinant soluble TNF p55 
receptor administered subcutaneously. A pilot study of 
onercept in patients with active CD showed beneﬁ  t at higher 
dose.136 A large, placebo-controlled, dose-ﬁ  nding study on 
207 patients with active CD showed a safe proﬁ  le but onercept 
was no effective at the doses studied for CD patients.137
Adalimumab
Adalimumab (ADA) is a fully human IgG1 monoclonal 
antibody to TNF-α that is administered subcutaneously. 
An uncontrolled pilot study demonstrated that adalimumab 
was well tolerated in patients with CD who lost response, 
or developed infusion reactions or delayed-type hypersen-
sitivity reactions to inﬂ  iximab.138 In the CLASSIC 1139 trial 
299 inﬂ  iximab-naïve patients with active CD were treated 
with adalimumab. An induction dose of 160 mg followed 
by 80 mg at week 2 achieved remission in 36% at week 4 
(versus 12% placebo). In the CLASSIC II140 trial, 276 patients 
enrolled in CLASSIC I received open-label ADA at week 0 
and 2; 55 patients in remission at both weeks 0 and 4 were 
re-randomized to ADA 40 mg every other week, 40 mg 
weekly or placebo for 56 weeks. At week 56 79% of patients 
who received ADA 40 mg every other week and 83% who 
received 40 mg weekly were in remission, compared with 
44% for placebo group.
In the CHARM141 trial, patients received open-label 
induction therapy with ADA 80 mg at week 0, followed 
by 40 mg at week 2. At week 4, patients were stratiﬁ  ed by 
response and randomized to double-bind treatment with pla-
cebo, ADA 40 mg every other week or ADA 40 mg weekly 
through week 56. The percentage of randomized responders 
in remission was signiﬁ  cantly greater in the ADA 40 mg Biologics: Targets & Therapy 2009:3 91
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every other week and 40 mg weekly groups vs placebo at 
week 26 (40%, 47% and 17%, respectively) and week 56 
(36%, 41%, and 12%, respectively).
In all studies adalimumab was well tolerated, with a 
safety proﬁ  le consistent with previous experience with the 
drug. Adalimumab is available for clinical use in patients 
with CD refractory to conventional therapy. Studies in UC 
are currently ongoing.
Inhibitors of proinﬂ  ammatory cytokine 
receptors
Anti IL-6R
A humanized monoclonal antibody against IL-6R (MRA) has 
been developed, and its efﬁ  cacy in the treatment of active CD 
was reported.142 Thirty-six patients with active CD refractory to 
conventional therapies were randomized to receive biweekly 
infusions of MRA or placebo, or an alternate MRA/placebo 
(every-4th-week MRA) regimen for 12 weeks at 8 mg/Kg. 
The response and remission rates in the MRA biweekly infu-
sion group were signiﬁ  cantly higher than in the placebo group 
(80% vs 31%; 20% vs 0%, respectively); however, the clini-
cal response of the every-4th-week regimen was only 42%. 
Infusions were well tolerated and, although promising, these 
preliminary data will need conﬁ  rmation from larger trials.
Inhibitors of Th1 polarization 
and proliferation
Anti-IL-2 receptor (CD25) antibodies (daclizumab 
and basiliximab)
Daclizumab is a recombinant humanized IgG1 monoclonal 
antibody to IL-2 receptor (CD25), which blocks the binding 
of IL-2 to the IL-2 receptor. An open label pilot study of 
daclizumab suggested that it was beneﬁ  cial for patients with 
active UC.143 However, a recent placebo-controlled phase II 
trial of daclizumab at intravenous doses of 1 mg/kg twice 
with a four-week interval or 2 mg/kg every second week for 
a total of four doses in 159 patients with active UC failed to 
show any efﬁ  cacy.144
A recent open-label, pilot trial evaluated the efﬁ  cacy of 
a chimeric monoclonal anti-CD25 antibody, basiliximab, as 
a steroid-sensitizing agent in steroid-resistant UC.145 Fifteen 
patients received basiliximab intravenously in addition to their 
standard steroid treatment and 80% achieved remission within 
six weeks. A large study, placebo controlled is required.
Anti-IL-12
In a multicentric, randomized, placebo-controlled, double-
blind, phase II clinical trial,146 the safety and efﬁ  cacy of a 
human monoclonal antibody against IL-12 was evaluated 
in 79 patients with active CD. Patients were randomly 
assigned to receive seven weekly subcutaneously injections 
of 1 mg/kg or 3 mg/kg of anti-IL-12 or placebo, with either 
a four-week interval between the ﬁ  rst and second injection 
(Cohort 1) or no interruption between the two injections 
(Cohort 2). Safety was the primary end point, and rates 
of clinical response (deﬁ  ned by a reduction in CDAI of at 
least 100 points) and remission (CDAI score of 150 or less) 
were secondary endpoints. Seven weeks of uninterrupted 
treatment with 3 mg/kg of anti-IL-12 resulted in higher 
response rates than did placebo administration (75% vs 
25%). At 18 weeks of follow-up, the difference in response 
rates was no longer signiﬁ  cant (69% vs 25%). Differences 
in remission rates between the group given 3 mg/kg and 
the placebo group in the Cohort 2 were not signiﬁ  cant at 
the end of treatment or at the end of follow-up (38% and 
0%, respectively, at both times). There were no signiﬁ  cant 
differences in response rates among the groups in Cohort 1. 
The rates of adverse events among patients receiving anti-
IL-12 were similar to those among patients given placebo, 
except for a higher rate of local reactions at injection sites 
in the former group.
Anti-IFN-γ (Fontolizumab)
Fontolizumab is a humanized monoclonal antibody to 
IFN-γ. In a phase I/II dose escalation study,147 28 patients 
with moderate-to-severe active CD were randomized to 
receive a single infusion of HuZAF, a humanized anti-IFN-γ 
monoclonal antibody, at 0.1 mg/kg, 1 mg/kg, or 4 mg/kg, 
or placebo. A dose-dependent effect was seen, with the 
highest response and remission rates achieved in the 4-mg 
group (86% vs 50% and 71% vs 33%, respectively). HuZAF 
was well tolerated, with a good safety proﬁ  le. The results 
of a larger, double-blind, placebo-controlled study of fon-
tolizumab in patients with moderate-to-severe CD were 
reported.148 In this study 133 patients with CDAI scores 
between 250 and 450 were randomized to receive placebo 
or 4 mg/kg or 10 mg/kg fontolizumab. The ﬁ  rst 42 patients 
received a single treatment; the subsequent 91 patients 
received two infusions (days 0 and 28). Fontolizumab had a 
beneﬁ  cial effect on disease activity in patients who received 
two infusions of drug. This effect was most prominent in 
patients with objective evidence of inﬂ  ammation as deﬁ  ned 
by an elevated concentration of CRP. Safety and tolerabil-
ity were good, but more information on long-term data, 
follow-up and duration of remission are needed to deﬁ  ne 
correctly its safety proﬁ  le.Biologics: Targets & Therapy 2009:3 92
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Adhesion molecule inhibitors
Natalizumab
Natalizumab is a recombinant, humanized IgG4 monoclonal 
antibody against α4 integrin. It inhibits both α4β7 integrin/
MAdCAM-1 interaction and α4β1/VCAM-1 binding.
Two phase II studies of intravenous natalizumab at doses 
of 3 mg/kg, 3 mg /kg every four weeks × 2 doses, and 6 mg/kg 
every 4 weeks × 2 doses showed signiﬁ  cant short-term beneﬁ  t 
for natalizumab in patients with active CD.149,150 A large 
phase III study in patients with active CD failed to show a 
beneﬁ  t for natalizumab 300 mg every four weeks × 3 doses, 
primarily due to an unexpectedly high placebo response rate.151 
A post hoc exploratory analysis of a subgroup of patients 
with elevated CRP concentrations above the normal range 
demonstrated a signiﬁ  cant effect for natalizumab compared 
with placebo.151 Patients who responded to natalizumab in the 
phase III induction study were re-randomized to maintenance 
therapy with natalizumab 300 mg or placebo every four weeks 
up to six months (natalizumab withdrawal study). This main-
tenance study demonstrated a highly signiﬁ  cant maintenance 
beneﬁ  t, with the difference between the treatment groups at 
six months exceeding 30%.152 Recently, the ability to taper 
or discontinue oral corticosteroids in patients treated with 
natalizumab, was evaluated in a randomized, double-blind, 
placebo-controlled, multicentric study (ENACT-2).153 The 
results of this study demonstrated that natalizumab seems 
to be associated with steroid-sparing effects in patients with 
CD as evidenced by the ability of the drug to sustain clinical 
response and/or remission over time following the withdrawal 
of concomitant corticosteroids.
Natalizumab 3 mg/kg e.v. has also demonstrated some 
evidence of clinical beneﬁ  t at two weeks post-infusion in an 
uncontrolled study in patients with active UC.154
Although these promising results, due to the report of two 
cases of polymyeloleukodystrophy (PML) in two patients 
receiving concomitant natalizumab and beta interferon. PML, 
which almost invariably occurs in patients with AIDS or 
leukemia or in organ-transplant recipients, is a fatal oppor-
tunistic infection of the central nervous system caused by 
reactivation of a clinically latent JC polyomavirus infection. 
The drug which was recently marketed for multiple sclerosis 
has been taken off the market but recently is re-marketed in 
USA also for CD with a lot of safety recommendations.
MLN-02
MLN-02 is a humanized immunoglobulin G1 (IgG1) 
monoclonal antibody against α4β7 integrin that selectively 
inhibits leukocyte adhesion in the gastrointestinal mucosa. 
Fc receptor recognition and binding has been detected, thus 
eliminating complement ﬁ  xation and cytokine release.
A randomized placebo-controlled trail155 185 patients 
with mild to moderately active CD were randomized to 
receive MLN-02 (0.5 or 2.0 mg/kg) or placebo on days 1 
and 29. At 2 months, neither treatment group achieved the 
primary endpoint, which was a statistically signiﬁ  cant differ-
ence from placebo in achieving clinical response (decrease 
of  70 points in CDAI score). There was a statistically sig-
niﬁ  cant difference seen between the 2.0-mg/kg and placebo 
groups (36.9% vs 20.7%) in achieving the secondary end 
point of clinical remission (CDAI score  150), and there was 
a trend toward dose response. The adverse events (nausea and 
nasopharyngitis) were more frequent in the MLN-02 treat-
ment groups, but no patients discontinued the treatment.
A phase I/II, double-blind, placebo-controlled, ascending-
dose trial examined the safety and pharmacology of MLN-02 
in 28 patients with moderately severe UC.156 Patients received 
a single dose of 0.15 mg/kg MLN-02 s.c., a single dose 
of 0.15. 0.5, or 2.0 mg/kg e.v. (groups 1–4), or placebo. 
A meaningful endoscopic response (deﬁ  ned as 2-grade 
improvement) was observed in 1/5, 0/5, 3/5, and 1/5 patients 
in groups 1–4, respectively, compared to 2/8 patients in 
the placebo group. In group 3, 40% of patients (0.5 mg/kg 
MLN-02) had complete endoscopic remission (deﬁ  ned as 
modiﬁ  ed Baron’s score of 0) and clinical remission (deﬁ  ned 
as a Mayo Clinic Score of 0). MLN-02 appears to be a gener-
ally well-tolerated and effective therapy especially for active 
UC, but further trials are necessary to conﬁ  rm the efﬁ  cacy 
of the drug in IBD.
Alicaforsen (ISIS 2302)
The interaction of lymphocyte-associated α1β2-integrin, also 
known as leukocyte function antigen (LFA)-1, and its ligand, 
intercellular adhesion molecule-1 (ICAM-1), is important 
for the recruitment of leukocytes to inﬂ  ammatory sites. ISIS 
2302, a 20-base phosphorothioate antisense oligodeoxynu-
cleotide, is designed to hybridize to a 3’ untranslated region 
of human ICAM-1 messenger ribonucleic acid (mRNA). The 
heterodimer formed is cleaved by ubiquitous ribonuclease H, 
resulting in a reduction in ICAM-1 protein expression.157
Initial positive results were reported in a pilot trial,158 
but two subsequent placebo-controlled trials failed to dem-
onstrate efﬁ  cacy. The ﬁ  rst involved 75 patients treated with 
subcutaneous ISIS 2302 0.5 mg/kg for durations of two days, 
one week, two weeks, four weeks, or placebo, and only 3.3% 
reached steroid-free remission at week 14.159 The second 
randomized 299 patients to receive intravenous ISIS 2302 Biologics: Targets & Therapy 2009:3 93
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at 2 mg/kg (three times weekly) for two or four weeks, or 
placebo.160 Although steroid-free remission rates were similar 
to those of the placebo group, pharmacodynamic analysis 
revealed a signiﬁ  cant relationship between drug exposure 
and response, which suggests that ISIS 2302 might have been 
effective when if given in adequate doses.
ISIS 2302 in enema formulation showed signiﬁ  cant 
improvement in 40 patients with distal UC in a randomized, 
placebo-controlled trial.161
Growth hormone and growth 
factors
Human growth hormone and a variety of growth factors 
such as TGF-β, which is secreted by Th3 cells and provides 
negative feedback on the differentiation of naïve T helper 
cells to Th1 or Th2 subtypes, epidermal growth factor (EGF), 
and keratinocyte growth factor-1 (KGF-1), may play an 
important role in IBD,162 for their potential use to heal and 
restore mucosal integrity.
Human growth hormone
Human growth hormone is a regulatory peptide that increases 
aminoacid and electrolyte uptake by the intestine, decreases 
intestinal permeability, and induces the expression of insulin-
like growth factor I, which in turn stimulates collagen synthe-
sis. The rationale for the use of growth hormone in CD is to 
reverse the catabolic process associated with inﬂ  ammation. In 
the only placebo-controlled trial,163 a signiﬁ  cant decrease in 
the CDAI score among 37 patients with moderate-to-severe 
CD who received subcutaneous growth hormone for four 
months, compared with placebo (143 ± 144 vs 19 ± 63), was 
demonstrated. However, the proportion of patients entering 
remission was not reported. Further controlled trials using 
the more conventional endpoints of improvement and remis-
sion are required.
Epidermal growth factor
Epidermal growth factor is a potent mitogenic peptide 
produced by salivary and duodenal Brunner’s glands which 
stimulates cell proliferation in the gastrointestinal tract. 
A phase II study of recombinant epidermal growth factor 
enemas demonstrated efﬁ  cacy in patients with active distal 
UC.164 Further trials are needed to conﬁ  rm these impressive 
results. Moreover and most importantly, of concern is the 
potential for malignant transformation with EGF therapy in 
UC patients, because it upregulates the expression of pro-
toncogens in patients with known cancer risk.
Sargramostim and ﬁ  lgrastim
Sargramostim (recombinant human granulocyte-macrophage 
colony stimulating factor) and filgrastim (recombinant 
human granulocyte colony stimulating factor) are hematopoi-
etic growth factors that stimulate cells of the innate immune 
system, including neutrophils, macrophages, and dendritic 
cells. They have been shown to be effective in the treatment 
of genetic syndromes resulting in neutrophil dysfunction such 
as glycogen storage diseases, Chediak-Higashi syndrome, 
and chronic granulomatous disease similar to CD.165,166 
Based on these observations, phase II trials were performed 
in patients with CD, and suggested that sargramostim and 
ﬁ  lgrastim may be of beneﬁ  t in patients with active and 
ﬁ  stulizing CD, possibly via an immunostimulant effect on 
neutrophils.167,168 In a randomized, double-blind, placebo-
controlled trial,169 124 patients with moderately-to-severely 
active CD (CDAI  220 and  475 points) were treated 
with 6 μg/kg/day sargramostim or placebo subcutaneously 
for 56 days.
At end of this treatment period, signiﬁ  cantly more sar-
gramostim than placebo patients showed a  100-point response 
(48% vs 26%) and clinical remission (40% vs 19%).
Conclusions: The state of art 
biologic agents in IBD
Biologic agents are facing expanding indications in IBD 
and will undoubtedly beneﬁ  t patients in the long-term. 
Inﬂ  iximab has a clear high efﬁ  cacy when administered early 
in the disease course, but more data are needed before it is 
positioned as a ﬁ  rst-line therapy. Inﬂ  iximab still needs to be 
administred intravenously and provides neither cure nor a 
durable effect after discontinuation.
The novel anti-TNF antibodies adalimumab and cer-
tolizumab pegol offer the perspective of subcutaneous 
out-of-hospital treatment. However both agents still have to 
stand up to the real world test of long-term therapy in a large 
patient population. The risk-beneﬁ  t ratio for a powerful drug 
such as inﬂ  iximab carries a limited risk of increased infec-
tions and possibly of lymphoma, particularly in combination 
with steroids and/or azathioprine.
With increasing knowledge about the pathogenesis of 
IBD and the mechanism driving the uncontrolled inﬂ  am-
mation, new agents have entered the arena. The selective 
adhesion molecule inhibitor, natalizumab, is now approved 
for CD in the USA, but development has been temporarily 
discontinued due to unexpected JC virus brain infections. 
With anti-IL-12 and anti-IFN-γ we are moving closer to 
the epicenter of immune reaction. This may result in higher Biologics: Targets & Therapy 2009:3 94
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efﬁ  cacy, but also may raise new safety issues that should be 
monitored closely.
With recombinant GM-CSF, sargramostim, first 
attempts at boosting the innate immune system are being 
made. Therefore, it is likely to be only a pioneering agent 
that may provide the proof of concept only to be succeeded 
by more selective agents targeted at the immune innate 
system. Only agents restoring T cell tolerance long term or 
repairing the basic dysfunction in the innate immune system 
may provide the perspective of cure in chronically remit-
ting and ﬂ  aring diseases such as IBD. In conclusion, unmet 
needs for medical treatment include: primary nonresponse 
to inﬂ  iximab, secondary loss of response to inﬂ  iximab in 
CD and UC and long-term ﬁ  stula healing in CD. Novel 
biologic treatments will probably be able to meet most of 
these needs, but combination therapy and tailoring of the 
management to the proﬁ  le of the patient will most likely 
be necessary.
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